Press release
Acute Bacterial Skin and Skin Structure Infections Market Sales, Size, Leading Player & Forecast to 2025
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI. This infection is difficult for treatment due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp. ABSSSI market is expected to exhibit growth at a trajectory rate, owing to increasing number of patients suffering from these and large number of pipeline products, expected to receive approved in the forecast period.Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1531
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Driver
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.
However, growth of the ABSSSI market is expected to be hindered by increasing incidence of resistant strains of causative agents, stringent regulatory policies by government bodies, and patent expiration.
Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to article published in 2015 of PLoS One journal, skin and skin structure infections related hospital admissions were 1.6% in 2005, increased to 2.0% in 2011. Moreover, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.
Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1531
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Regional Analysis
Globally, acute bacterial skin and skin structure infections (ABSSSI) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominate position in ABSSSI market, and this is attributed to large number of pipeline products by the regional market players. However, Asia Pacific is expected to witness fast growth, owing to increasing awareness of ABSSSI treatment and manufacturers’ geographical expansion. For instance, Basilea Pharmaceutics Ltd. signed an agreement with Shenzhen China Resources Gosun Pharmaceutical Co., in year 2017, to treat Methicillin resistant Staphylococcus aureus infection in China, Hong Kong and Macao by Basilea’s Zevtera.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Competitor
Key players in the global acute bacterial skin and skin structure infections (ABSSSI) market are Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Fresenius SE & Co. KGaA, Sandoz Inc. (a subsidiary of Novartis), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva Pharmaceutical Industries Ltd. The ABSSSI market players are involved in strategic planning for expanding the market share of the company. For instance, in 2014, Merck & Co., Inc. acquired Cubist Pharmaceuticals for US$ 9.5 billion. The acquisition will strengthen product portfolio by acquiring presently marketed and late stage pipeline products. Moreover, in 2017, Cempra, Inc.— a clinical-stage pharmaceutical company focused on developing treatment of infectious diseases—merged with Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections. The merger will commercialize the launch of Melinta’s Baxdela, a fluoroquinolone based ABSSSI treatment for susceptible bacteria.
Get More Details About This Report @ https://www.coherentmarketinsights.com/ongoing-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Taxonomy
By Active Ingredient: Delafloxacin, Vancomycin, Ceftaroline fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Others,.
By Route of Administration: Oral, Parenteral, Topical,.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies,.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
1001 4th Ave,, #3200, Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Bacterial Skin and Skin Structure Infections Market Sales, Size, Leading Player & Forecast to 2025 here
News-ID: 1033763 • Views: …
More Releases from CMI Research Report

Hospital Beds Market worth US$ 5.2 Billion by 2025 Globally
Many of the hospitals have shifted their capital funds towards the hospital infrastructure, which is mainly seen in private hospitals. Improving healthcare amenities along with increasing spending in healthcare is expected to boost growth of hospitals beds market globally. Increasing number of geriatric population and need for their treatment is expected to fuel the growth of hospital bed market over the forecast period. The number of hospital beds are very…

Adrenocortical Carcinoma Treatment Market 2017 Industry Analysis, Segment & Fore …
Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly caused due to tumors causing excess…

Primary Biliary Cirrhosis Drugs Market Overview, Trends and Growth Opportunities …
Primary biliary cirrhosis, known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis includes itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation,…

Orthopedic Medical Imaging Market Trends and Drivers Analysis 2017 - 2025
Orthopedic medical imaging allows doctors to non-invasively examine the internal structure of the body for aiding in diagnosing a medical condition. Medical imaging devices identify and monitor diseases or injuries by generating images representing internal anatomic structures of the patient's body. Orthopedic medical imaging has proved to be an informational tool that has helped physicians to diagnose the disease and response of the treatment. Orthopedic medical imaging deliver safe, effective,…
More Releases for ABSSSI
Revolutionizing Care: Breakthroughs Propel the ABSSSI Treatment Market into a Ne …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) represent a significant clinical and economic burden worldwide, affecting patients across outpatient clinics, hospitals, and long-term care facilities. From simple cellulitis to complex wound infections, these conditions require prompt, effective therapy to prevent serious complications and reduce healthcare costs. Today, the ABSSSI treatment market is undergoing a renaissance, driven by novel antibiotic classes, innovative delivery systems, and a heightened focus on antimicrobial…
ABSSSI Therapeutics Market Size in the 7MM is anticipated to increase by 2034 an …
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Bacterial Skin and Skin Structure Infections, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin Structure Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the ABSSSI Market! Download…
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Treatment Market Size …
Acute Bacterial Skin and Skin Structure Infections Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Acute Bacterial Skin and Skin Structure Infections Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market 2022-2028 | P …
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Detailed …
Acute Bacterial Skin and Skin Structure Infections Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Acute Bacterial Skin and Skin Structure Infections depending on the industry's financial and non-financial impact. The complete range of information…
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Rapidly Devel …
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based…